Takeda Pharmaceutical Co. Ltd. reported a decrease in revenue to JPY 1,106.7 billion for the three months ending June 30, 2025, a decline of 8.4% from the previous year, largely due to foreign exchange impacts and decreased sales in Neuroscience, particularly from VYVANSE. The company also reported a net profit increase of 30.4% to JPY 124.3 billion, reflecting growth in other business areas despite overall revenue drop.